# Sampling Human

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sampling-human

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.samplinghuman.com
- Total disclosed funding: $2M
- Latest round: Seed (Apr 13, 2022)
- Investors on record: 3

## About

Based in California, US, and founded in 2016 by CEO Daniel Georgiev, Martin Cienciala, and Hynek Kasl, Sampling Human, Inc. is a biotechnology research company that develops and provides a platform that harnesses genetically engineered cells to analyze other cells in their environment, enabling research institutions and clinicians to solve problems in diagnostics and bioengineering. In April 2022, Sampling Human, Inc. raised USD 2 million in venture funding led by i&i Biotech Fund, with participation from Formic Ventures and Longevity Tech Fund.

Sampling Human provides diagnostic reagent kits used for liquid biopsy of diseased and healthy cells as well as harnessing living cells in order to analyze other cells. The company also offers Diagnostics On Target (DOT), a novel platform built with diagnostics technology to translate single-cell data into clinical practice for enhancing the monitoring of early disease detection and treatment. In addition, the firm manufactures and designs tools to eradicate sensitivity and upsurge the speed of investigative procedures higher than instruments like flow cytometry.

The company plans to use its proceeds from April 2022 funding to further accelerate hiring, advance research and development, and business development.

## Funding rounds

- Seed, Apr 13, 2022, $2M — Formic Ventures, Longevity Tech Fund, i&i Bio

## Investors

- Formic Ventures (https://capitalatlas.ai/funds/formic-ventures) — Seed
- Longevity Tech Fund (https://capitalatlas.ai/funds/longevity-tech-fund) — Seed
- i&i Bio (https://capitalatlas.ai/funds/i-i-bio) — Seed